About C3G

FOR ADULT PATIENTS WITH C3G

Patients with C3G can face significant disease burden¹

Patients with C3G can face significant disease burden.

Elevated proteinuria can be an ongoing challenge for those living with C3G¹

Although C3G can affect people of all ages, the median age at diagnosis is 23 years old⁴

Managing persistent proteinuria is critical for patients like Felix^1,2

Meet Felix, a 27-year-old male with C3G.

In the last 6 months, Felix's UPCR has worsened

6 MONTHS AGO^5,6

UPCR: 1.5 g/g
BP: 135/95 mm Hg

CURRENT PRESENTATION^5,6

UPCR: 2.8 g/g
BP: 145/95 mm Hg

CLINICAL NOTES:

Since his C3G diagnosis 2 years ago, Felix has been treated with maximally tolerated RASi, 2 courses of MMF, and corticosteroids⁵
As a busy individual, Felix is seeking an oral treatment option that aligns with his lifestyle while effectively reducing his proteinuria

How would you manage C3G in patients like Felix who are living with persistent proteinuria?

See how FABHALTA works

See trial results for FABHALTA

Definitions and References

Definitions
BP, blood pressure; C3G, complement 3 glomerulopathy; MMF, mycophenolate mofetil; MOA, mechanism of action; RASi, renin-angiotensin system inhibitor; UPCR, urine protein-to-creatinine ratio.

References
1. Data on file. Natural History of C3G Glomerulopathy. Novartis Pharmaceuticals Corp; June 2024.
2. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46-53. doi:10.2215/CJN.04700513
3. Data on file. Study CLNP023B12301 CSR. Novartis Pharmaceuticals Corp; December 2023.
4. Martín B, Smith RJH. C3 Glomerulopathy. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews. Seattle (WA): University of Washington, Seattle. Published July 20, 2007. Updated April 5, 2018.
5. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.
6. Data on file. C3G Patient Case Study. Novartis Pharmaceuticals Corp.